KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Net Cash Flow (2016 - 2025)

Biogen (BIIB) has 17 years of Net Cash Flow data on record, last reported at -$856.8 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 214.21% year-over-year to -$856.8 million; the TTM value through Dec 2025 reached $531.6 million, down 61.83%, while the annual FY2025 figure was $531.6 million, 61.83% down from the prior year.
  • Net Cash Flow reached -$856.8 million in Q4 2025 per BIIB's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.1 billion in Q3 2025 and bottomed at -$1.3 billion in Q4 2023.
  • Average Net Cash Flow over 5 years is $86.2 million, with a median of -$16.6 million recorded in 2021.
  • The widest YoY moves for Net Cash Flow: up 718.59% in 2022, down 522.92% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at $735.4 million in 2021, then tumbled by 143.99% to -$323.5 million in 2022, then tumbled by 297.5% to -$1.3 billion in 2023, then skyrocketed by 158.34% to $750.2 million in 2024, then plummeted by 214.21% to -$856.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$856.8 million in Q4 2025, $1.1 billion in Q3 2025, and $92.2 million in Q2 2025.